Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
TEXT: Mapping Customer Journeys in a Digital World
Summary
In this episode, Tom Caravela is joined by Mitchell D’Rozario to explore the challenges and strategies in engaging with Key Opinion Leaders (KOLs). They discuss the importance of understanding digital communication preferences and establishing value through effective timing and methods. The conversation delves into leveraging publication history and digital tools to enhance MSL access and engagement, while balancing virtual and in-person interactions. They highlight the role of compassionate leadership, navigating social media, and adapting strategies in difficult times. Mitchell shares insights on overcoming obstacles, learning from failures, and provides tips for aspiring MSLs.
Mitchell D’Rozario, Medical Science Liaison at Genentech discusses digital tools and techniques for MSLs to Map Customer Journeys: pain points and opportunities.
Mitch shares…
👉 How to go about developing a TEXT relationship with your Key Opinion Leaders
👉 What key questions you should be asking
👉 How and why the use of social media is so important
👉 Unique ways to engage with KOLs and gain better access
👉 Advice on performance and meeting goals
Key Opinion Leaders, Digital Communication, Medical Science Liaison, Social Media Engagement, Compassionate Leadership
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
iNIZIO